Immune evasion is a key strategy adopted by tumor cells to escape the immune system while promoting their survival and metastatic spreading. Indeed, several mechanisms have been developed by tumors to inhibit immune responses. PD-1 is a cell surface inhibitory receptor, which plays a major physiological role in the maintenance of peripheral tolerance. In pathological conditions, activation of the PD-1/PD-Ls signaling pathway may block immune cell activation, a mechanism exploited by tumor cells to evade the antitumor immune control. Targeting the PD-1/PD-L1 axis has represented a major breakthrough in cancer treatment. Indeed, the success of PD-1 blockade immunotherapies represents an unprecedented success in the treatment of different cancer types. To improve the therapeutic efficacy, a deeper understanding of the mechanisms regulating PD-1 expression and signaling in the tumor context is required. We provide an overview of the current knowledge of PD-1 expression on both tumor-infiltrating T and NK cells, summarizing the recent evidence on the stimuli regulating its expression. We also highlight perspectives and limitations of the role of PD-L1 expression as a predictive marker, discuss well-established and novel potential approaches to improve patient selection and clinical outcome and summarize current indications for anti-PD1/PD-L1 immunotherapy.

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects / Munari, Enrico; Mariotti, Francesca R; Quatrini, Linda; Bertoglio, Pietro; Tumino, Nicola; Vacca, Paola; Eccher, Albino; Ciompi, Francesco; Brunelli, Matteo; Martignoni, Guido; Bogina, Giuseppe; Moretta, Lorenzo. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 22:10(2021), pp. 1-18. [10.3390/ijms22105123]

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects

Eccher, Albino;
2021

Abstract

Immune evasion is a key strategy adopted by tumor cells to escape the immune system while promoting their survival and metastatic spreading. Indeed, several mechanisms have been developed by tumors to inhibit immune responses. PD-1 is a cell surface inhibitory receptor, which plays a major physiological role in the maintenance of peripheral tolerance. In pathological conditions, activation of the PD-1/PD-Ls signaling pathway may block immune cell activation, a mechanism exploited by tumor cells to evade the antitumor immune control. Targeting the PD-1/PD-L1 axis has represented a major breakthrough in cancer treatment. Indeed, the success of PD-1 blockade immunotherapies represents an unprecedented success in the treatment of different cancer types. To improve the therapeutic efficacy, a deeper understanding of the mechanisms regulating PD-1 expression and signaling in the tumor context is required. We provide an overview of the current knowledge of PD-1 expression on both tumor-infiltrating T and NK cells, summarizing the recent evidence on the stimuli regulating its expression. We also highlight perspectives and limitations of the role of PD-L1 expression as a predictive marker, discuss well-established and novel potential approaches to improve patient selection and clinical outcome and summarize current indications for anti-PD1/PD-L1 immunotherapy.
2021
22
10
1
18
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects / Munari, Enrico; Mariotti, Francesca R; Quatrini, Linda; Bertoglio, Pietro; Tumino, Nicola; Vacca, Paola; Eccher, Albino; Ciompi, Francesco; Brunelli, Matteo; Martignoni, Guido; Bogina, Giuseppe; Moretta, Lorenzo. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 22:10(2021), pp. 1-18. [10.3390/ijms22105123]
Munari, Enrico; Mariotti, Francesca R; Quatrini, Linda; Bertoglio, Pietro; Tumino, Nicola; Vacca, Paola; Eccher, Albino; Ciompi, Francesco; Brunelli, ...espandi
File in questo prodotto:
File Dimensione Formato  
ijms-22-05123.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 760.59 kB
Formato Adobe PDF
760.59 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1317479
Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 61
social impact